万赛维治疗CMV视网膜炎的疗效好吗？

It is an antiviral drug produced by the Swiss company Roche. It is used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

Human viruses to which Valganciclovir is sensitive include human cytomegalovirus (HCMV), valganciclovir hydrochloride to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus. So how effective is Vancevi in ​​the treatment of CMV retinitis? Many patients are concerned about this issue.

Clinical studies of CMV retinitis in AIDS patients infected with CMV retinitis have shown that Vancevir tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Vancevir tablet group or the intravenous Vancevir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Vancevir tablets at a dose of 900 mg per day. Among patients who received Vancevir tablets or intravenous Vancevir tablets for induction therapy followed by Vancevir tablets for maintenance therapy, the mean (median time) from randomization to worsening of CMV retinitis was: 226 (160) days and 219 (125) days.

Clinically, the antiviral effect of Vancevir tablets has been confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with Vancevir tablets, and the U.S. Food and Drug Administration (FDA) approved the increased use of the tablets in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.